Global Analysis of Active Pharmaceutical Ingredient (API)

Background:

“A substance used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the cure, diagnosis, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in humans,” is how the World Health Organization (WHO) defines active pharmaceutical ingredients (API).

Active Pharmaceutical Ingredient (API) is an active product that has completed the synthetic pathway. The API can be prepared directly, while the intermediate can only be used to synthesize the next product. It is only through the middleman that the API can be manufactured.

The global supply of API is particularly concentrated depending on the export situation in regulated markets. The top seven countries account for 76 percent of the global supply of API in regulated markets, with the U.S. accounting for the highest proportion, about 36 percent, followed by India, China, Italy and Japan, with 2 percent, 9 percent, 7 percent, 6 percent and 4 percent, respectively. Currently, China is one of the world's largest API producers and the world's largest API exporter, occupying an influential position in the international market.

However, from the perspective of the distribution of the global API industry chain, China is at the upstream of the industry chain and its added value is relatively low, leading to a large but not strong performance of Chinese API in the world.

Due to the low technical threshold of traditional bulk API, the number of domestic manufacturers of traditional bulk API showed rapid growth in the early stage, and the output scale once increased by approximately 25 million tons, leading to the excess capacity of traditional bulk API at the present stage in China. Traditional bulk API production began to decline from 2017, dropping to 17.9628 million tonnes in 2018. As of 2019, the total domestic API production was 18.905 million tons.

China's API has been exported to 189 countries and regions. Major exports are concentrated in Asia, Europe and North America, which together accounted for 89 percent of China's total API exports in 2019. Among them, the export of API from the Asian market reached 5,446,100 tons, with a value of $15.917 billion, up by 15.56% year-on-year. India is the largest exporter of Chinese API, with 70 percent of its API coming from China. It exported 2.07763 million tons of API to Europe, with a value of $9.461 billion. Exports to the European Union reached $8.281 billion, up 12.36 percent year-on-year. The export of API to North America was 787,900 tons, with a value of $4.518 billion, down 0.37% year-on-year.

There are numerous types of medical intermediates, which can be divided into large categories based on application areas, such as antibiotic intermediates, antipyretic and analgesic intermediates, cardiovascular intermediates, and cancer intermediates. There are a wide range of specific medical intermediates, such as imidazole, furan, phenolic intermediates, aromatic intermediates, pyrrole, pyridine, biochemical reagents, sulfur, nitrogen, halogen compounds, hetero-cyclic compounds, starch, mannitol, micro-crystalline cellulose, lactose, dextrin, ethylene glycol, sugar powder, inorganic salts, ethanol intermediates, stearates, amino acids, glycol-amines, potassium salts, sodium salts and other intermediates and so on.

Upstream of pharmaceutical intermediates is the basic chemical feedstock industry. As a bulk commodity, the prices of basic chemical raw materials fluctuate considerably, which directly affects the production costs of enterprises.

However, medical intermediates are subdivided into primary intermediates and advanced intermediates. As primary intermediate suppliers can only provide simple intermediate production, they are at the front end of the industrial chain and have the greatest competitive pressure and price pressure. They are heavily affected by fluctuations in the price of basic chemical raw materials. On the other hand, advanced intermediates suppliers not only have strong bargaining power over primary suppliers, but more importantly, they are less affected by raw material price fluctuations because they take on the production of advanced intermediates with higher technical content and maintain closer ties with multinational companies.

Active Pharmaceutical Ingredient (API) Market Analysis and Forecast

With the recent analysis of the global Active Pharmaceutical Ingredient (API) market finds that increasing incidence of chronic diseases is expediting market growth. Primarily driven by growing importance of generics, the total Global Active Pharmaceutical Ingredient (API) Market is estimated to reach USD 251.3 billion by 2028, up from USD 182.5 billion in 2020, at a compound annual growth rate (CAGR) of 6.20%.

Furthermore, the growing adoption of AI-based tools for drug discovery is also anticipated to augment the growth of the Global Active Pharmaceutical Ingredient (API) Market.

The Active Pharmaceutical Ingredient (API) market was valued at USD 300,722.26 billion in 2021 and is expected to reach at value of USD 540335.81 billion by 2029 at a CAGR of 7.6% during the forecast period of 2022 to 2029. The rising prevalence of various chronic diseases and an ageing population are the major drivers driving the Active Pharmaceutical Ingredient (API) market during the forecast period.

The Active Pharmaceutical Ingredient (API) market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, indications, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Active Pharmaceutical Ingredient (API) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Due to rising healthcare expenditures and well-established healthcare infrastructure, the United States dominates the North America API market. The small molecule segment in North America is expected to grow at the fastest rate during the forecast period of 2021 to 2028. China is leading the growth of the Asia-Pacific Active Pharmaceutical Ingredient (API) market, and the small molecule segment is dominating in the country as Active Pharmaceutical Ingredient (API) become more affordable. Due to increased consumption demand for active pharmaceutical ingredients, Germany's small molecule segment dominates the Europe Active Pharmaceutical Ingredient (API) market.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Market Dynamics:

Growing Adoption of AI-based Tools for Drug Discovery to Fuel Global Active Pharmaceutical Ingredient (API) Market.

The implementation of AI in the development of a medicinal and pharmaceutical product has aided in rational drug design. AI is used in target discovery and early drug discovery to analyze data sets, form hypotheses and generate novel insights, identify novel drug candidates, analyze data from patient samples in both healthy and diseased states to generate novel biomarkers and therapeutic targets and to predict binding affinity and other pharmacological properties of molecules, among others. Furthermore, AI can also be used in re-purposing of existing drugs for rapidly identifying new indications for many known drugs, match existing drugs with rare diseases, conduct experimental biology at scale by testing 1000+ of compounds on 100+ of cellular disease models in parallel and generate novel biomarkers and therapeutic targets. Additionally, it can be also optimizing clinical trial study design.      Owing to the increasing applications of AI in pharmaceutical industry the Active Pharmaceutical Ingredient (API) market is expected to grow in near future.

Increasing Incidence of Chronic Diseases to Stimulate the Market Growth

According to WHO, noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 71% of all deaths globally and more than 15 million people die from a NCD between the ages of 30 and 69 years; 85% of these "premature" deaths occur in low- and middle-income countries.

Furthermore, cardiovascular diseases account for most NCD deaths or 17.9 million people annually, followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). As the occurrences of these diseases are increasing the demand for more precise and effective drugs are also increasing.Additionally, percentage of various other diseases has also shown substantial increase which is further expected to support the growth of the API market in the years to come.

COVID-19 Impact Analysis:

The COVID-19 outbreak has affected various industries worldwide. Governments across the world implemented strict lockdown measures and social distancing norms in order to restrict the swift spread of the pandemic. Manufacturing facilities around the world were shut down during the initial stages of the pandemic. Moreover, the economic crisis after the pandemic might lead to a significant delay in the commercial roll-out of the healthcare industry. Small and medium-scale companies are the backbone of technology providers and are witnessing a steep drop in revenue since the emergence of the pandemic in 2020. Hence, market players faced numerous challenges as disruptions in the supply chain were observed. However, things will improve in the second half of 2022 as more supplies will come online. The impact of COVID-19 on the market demand is considered while estimating the current and forecast market size and growth trends of the market for all the regions and countries based on the following data points:

1. Impact Assessment of COVID-19 Pandemic

(1) North America

(2) Europe

(3) Asia Pacific

(4) Latin America

(5) Middle East & Africa

1. lQuarterly Market Revenue Forecast by Asia Pacific 2020 & 2021
2. lKey Strategies Undertaken by Companies to Tackle COVID-19
3. lLong Term Dynamics
4. lShort Term Dynamics

Regional Analysis:

North America Dominates the Global Active Pharmaceutical Ingredient (API) Market

North America projected to hold largest share in the Active Pharmaceutical Ingredient (API) market during the forecast period. This is attributable to the increase in occurrences of chronic diseases and rising demand for specialty drugs in the region. Additionally, the growing importance of generics and Investments in real-world evidence by pharmaceutical companies is also expected to2028)".

Active Pharmaceutical Ingredient (API) Market Scope and Segmentation

For examples:

Ademetionine disulfate tosylate：

S-Adenosyl-L-Methionine Disulfate P-Toluene-Sulfonate is the disulfate salt of the stable p-toluene-sulfonate complex of s-adenosyl-L-methionine (SAMe) with chemo-preventive activity. SAMe disulfate p-toluene-sulfonate undergoes hydrolytic conversion to its active compound SAMe within cells. Although the mechanism of action is largely unknown, SAMe attenuates experimental liver damage and prevents experimental hepato carcino genesis. In addition, SAMe may reduce mitochondrial cytochrome C release, caspase 3 activation, and poly (ADP-ribose) polymerase cleavage, and attenuate okadaic acid-mediated hepatocyte apoptosis in a dose-dependent manner. SAMe is an essential compound in cellular transmethylation reactions and a precursor of poly-amine and glutathione synthesis in the liver; SAMe deficiency is associated with chronic liver disease-associated decreases in the activity of Methionine Adenosyl Transferase 1A (MAT1A), the enzyme that catalyzes the production of SAMe as the first step in methionine catabolism.

Applications:

Ademetionine disulfate tosylate is a diastereoisomer of adenosine methionine ion in the form of a bisulfide-toluene sulfate mixed salt. Ademetionine (adenosine methionine) has anti-inflammatory activity and is used to treat chronic liver disease.

Types of Application:

l Medical raw materials: to improve the mood, maintain the liver, and delight the joints; amino acids.

l Raw materials for chemical pharmaceuticals: biochemical reagents - amino acids. Raw materials for health care products.

l Pharmaceutical APIs - raw materials for research.

l Agricultural and veterinary raw materials.

l Industrial chemical industry.

l Food additives.

l General purpose biochemical reagent - Amino acid.

Levomefolate calcium: 

Levomefolate calcium is an organic calcium salt of (6S)-5-methyltetrahydrofolic acid. It is sold under the brand name Metafolin and incorporated in Deplin. It is a form of Vitamin B that is used to treat megaloblastic anaemia, depression, as well as renal and hepatic impairment.

Applications:

This product is a calcium salt of L-5-methyltetrahydrofolate, a folate vitamin (vitamin B9, folate), which is a coenzyme form of folate. L-5-methyltetrahydrofolate (5-mthChemicalbookf) is a naturally occurring salt-forming methyl derivative form of folate. 5-mthf is also known as L-methylfolate. It is the most biologically active and functional form of folate, and is easier to absorb than ordinary folate.

Folic acid deficiency reduces the ability of cells to synthesize and repair DNA.  Folic acid supplementation may be a more favorable way to increase folic acid to lower homocysteine levels and support normal cell proliferation and vascular endothelial function.  Cardiovascular disease, nervous system function, and especially 5-MTHF supplementation during pregnancy have been shown to reduce the risk of neural tube malformations and recurrence.

There are two main metabolic pathways involved in the conversion of co-folic acid to L-methylfolic acid: methylation and DNA synthesis. The only form of free folate found naturally in human plasma and cells is 5-MTHF.

Folic acid deficiency is generally due to insufficient absorption of vitamin B as a result of vitamin deficiency. Extra folate is needed during pregnancy and breastfeeding, as well as during child development. Folic acid supplementation is required because folate-rich foods do not provide adequate doses under the influence of changes in absorption or metabolism or medications.

Bioactive biochemical pathways of folate involve a wide range of enzyme reactions and cofactors.  The absorbed folic acid is reduced and methylated to 5-MTHF during the metabolism of intestinal mucosal cells. This conversion is limited and does not alter the appearance of folic acid in the circulation.  The methionine is subsequently converted to s adenosine methionine (SAMe).  Methyl donors are involved in a number of biochemical processes.  It can also be used as a donor to participate in nucleotide synthesis, supporting the biosynthesis of DNA

Types of Application:

l Medical intermediates.

l The fortifying agent.

l Food additives.

l Medicine anti-anemia drugs.

l Raw material for the product - calcium folate; vitamin derivatives.

l Chemical product API.

l Chemical intermediates.

l Raw materials for the study.

Esmolol: 

Esmolol, also known as Elol, Emolol, Brevibloc, chemical name 4{[3-[(1-Methylethyl) amino]-2 hydroxyl] propoxy} methyl phenylpropionate hydrochloride, code name ASL-8052, was developed by CriticalCare in 1982, USA. First marketed in the United States in 1987, Chemicalbook is an ultra-short-acting cardioselective β1-receptor blocker. It has no intrinsic sympathetic activity and membrane stabilizing effect at therapeutic doses, but also has inhibitory effect on tracheal and vascular smooth muscle β2 receptors at large doses. It is characterized by rapid action and short acting time. Clinically, it is used primarily for supraventricular tachycardia during anesthesia. It may also be used in the event of myocardial infarction or after myocardial infarction, in acute unstable angina complicated by hyperventricular tachycardia, and in the case of perioperative, narcotic rapid treatment of hypertension.

Applications:

A rapid acting selective adrenalineβ1 blocker with a short duration of action. It mainly acts on the β1 receptor of the myocardium, and also blocks the β2 receptor of trachea and vascular smooth muscle in large doses. There was no intrinsic sympathomimetic effect or membrane stabilization at the therapeutic dose. Anti-arrhythmic effects are primarily achieved by inhibiting the stimulation of the pacemaker by adrenalin and slowing the conduction of the atria. The main sites of action are the conduction system at the sinoatrial node and at the apical node. The mechanism of anti-hypertensive action is not completely understood. It is similar to propranolol, but with the same β-blocking effect, it can lower blood pressure more than other selective and non-selective β-blockers such as metoprolol and propranololol.

The effect was effective from 3 to 5 min after intravenous administration, and peaked at 6 to 10 min for a duration of 20 min. The half-life was 9.2 min. In the bloodstream, it is rapidly hydrolyzed by erythropoietin to inactive metabolites and methanol..0.6% to 0.98% is excreted in urine as a prototype.

1. In the treatment of rapid supra-ventricular tachycardia, the effective rate is 66 - 79%.  It is also used in the treatment of atrial fibrillation and atrial flutter, with an effective rate of 76% and 60% respectively.

2. Coronary heart disease, angina pectoris.

3. Postoperative hypertension.

Types of Application:

l Chemical impurity - Vitamin B1(thiamine hydrochloride)

l Raw material drug

l Organic intermediate